# Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial

> **Open Intelligence Dossier** · First detected: 2026-11-09 07:00 UTC · Category: Health

## Executive Summary
The ZEUS clinical trial found that the anti-inflammatory drug ziltivekimab did not reduce major cardiovascular events in high-risk patients.

## Intelligence Brief
Heart researchers at the American Heart Association annual meeting in Chicago unpacked the neutral findings from ZEUS, a major anti-inflammatory clinical trial. According to MedPage Today, the global phase 3 trial tested ziltivekimab, a monoclonal antibody designed to target interleukin-6 (IL-6). While the treatment substantially reduced inflammatory markers, including free IL-6 and high-sensitivity C-reactive protein (CRP), it failed to reduce the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Paul M. Ridker, MD, of Harvard Medical School and Mass General Brigham Hospital reported that over a median follow-up of 33 months, primary endpoint events occurred in 561 patients in the ziltivekimab group and 565 patients in the placebo group. Medical Xpress noted that ZEUS enrolled patients with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation who were a decade older, had significant kidney disease, and often suffered from longstanding diabetes and heart failure compared to populations in earlier successful trials like CANTOS. Ridker explained that in such patients with advanced disease, &quot;the horse may already have been out of the barn,&quot; suggesting that targeting a downstream molecule like IL-6 may have been applied to the wrong, highly advanced patient population. BioSpace reported that following the topline results released in July 2026, Novo Nordisk ended several studies of ziltivekimab, including HERMES and ATHENA, but allowed the Phase 3 ARTEMIS trial in acute settings to continue. Discussant Priscilla Hsue, MD, questioned whether the drug was given too late or if targeting the ligand rather than the receptor was the wrong strategy. Despite the neutral trial outcome, researchers emphasized that inflammation remains a critical treatment target. MedPage Today and Medical Xpress reported that clinicians can still utilize lifestyle measures and available drugs such as statins, GLP-1 receptor agonists, and colchicine, which has been shown to reduce cardiovascular risk.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Medical Daily | Ziltivekimab sharply lowered CRP—but the ZEUS trial found no reduction in heart attacks, strokes or cardiovascular deaths | [Source Link](https://news.google.com/rss/articles/CBMifEFVX3lxTE1GSHRfRy1PUTA5RUtjb3dHTEpzTE5MSTR3alp4eGtQcTBoRnlIajZlQTZOYVY3VFg0MzIyQ3NodHMyRTJ1UFhvV20zY0NZVS1NeFpmWkNmUjdObUtpWWR1eFo5dHNGMU5hakpjLWM3aGhWWjlENzVhMFRXai0?oc=5) |
| Oncodaily | Dipender Gill Raises Questions About Cardiovascular Risk and IL-6 Inhibition in ZEUS | [Source Link](https://news.google.com/rss/articles/CBMiX0FVX3lxTE1FUW1sZVJtWXM2LVFpU1dJNWZoaEhrVFVJMlhhUzlXNVhrUEN4a3RMdXJWZjN3enNVWE9ldG0yQXBSMVpvQTVVbmtKZ0tpcEZxdlhfUkgtR2JWZWZBcWRR?oc=5) |
| STAT | Heart association meeting’s readout is trending ‘neutral’ | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxPUVFEWUdESjFrbHREWUhyMHp1WExjNDVvSEN0ZEdpQUV5MjB3a3p2ZDVySkJBMTZkeVFMc1VFb1NxZzVwQ3NPWF9hMzYxcDBvaEl4UWtrQVF1QTUyQTQwYWFFLXZqQ0c4ZVMzaUktTjFaQXprTndJeHJSYjZzdlBRSUJJb25SSWtLVmt1c2YxM3VHMmhD?oc=5) |
| BioSpace | Novo’s troubled cardio drug could find niche in less sick patients | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUkxKaTBsM3ZSQkxWUVgyNWIzV2Z3Q3prMDh2Q2RyY1RaY0ZLa0ZwUTdKS3BuU2RsMWZzemJ2Zk54X2hWdllORnctb1ZoX0s2cTdDVVNzWUtGR002Zm1VN0tqbFZ3SkVLOWNkay1NUHZYdEtfZ0FLM3JXamJnZDhaTmJlTUxJdlVpbHIxMDg1czBiV3NvZDZ2TE10LWxuckRSOGd3bXVja2kxYmM?oc=5) |
| TCTMD.com | ZEUS: What Went Awry With Ziltivekimab in Inflammation—and What Now? | [Source Link](https://news.google.com/rss/articles/CBMijgFBVV95cUxQdUJIcThDd05iRnVoQktSSjdab2E4ZDlJcHJIenVLNGhvZUNBX1N2MkZqLXJiVG92b1k4dUFYdFAwR1dEbEsySWxRUktVOHJ4eDV5VEd6Sk9GRGx5Ymh0N2JkYU5EdjI0alRDWnV1NlZwSlRqRWtrVGhJVTMxbjF3Q05ubmo2RWFPS2dmMVNn?oc=5) |
| MedPage Today | Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD | [Source Link](https://news.google.com/rss/articles/CBMiZkFVX3lxTE9TblN6VGYwb0M1MmV0V1U4Tzd4YWdqVEtQZFdFVTBfcUNGY1BaQ1FIRVV0VXNVa3lFUUE3Sl9JeE4yaTZ5ckdJWXNSVW1pWTFONTVXYTY2YTZIVkw5bWNSWlNWb2RKUQ?oc=5) |
| FirstWord Pharma | AHA26: Ziltivekimab shows inflammation control, but no MACE protection | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE9uMnhJdGY0R0dLbE5xT3ZnZXJLNG1XQlN1YlBNNXUzTms4UU84M2pibjduOUd6WVppazZQTjQwaGo5MVhleGhPM01aSE9WS2ctdk9F?oc=5) |
| STAT | Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxNQS05c1RPRjVlUjk4dER5TzkwbUlLVEJua0I3NVFENm5WaGFvOHU0eXJ2VXFOenBDQUp2NlFtV1pVOVRzdDI2WUdBOUlwbnhhRnlzeVJWUVlyVHZEUzNJSG1uZlZOb3JRZGRxc291REVscUtYbnR1TWlUdkhfWXFhUWx4R0dzeFJnUUZ4by1xenRSajQ2ZmZOREhZU25ZcTZFcFVn?oc=5) |
| Medical Xpress | Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial | [Source Link](https://news.google.com/rss/articles/CBMihwFBVV95cUxPNktrR3B3bWlpZVhUZEZSbUVQdm5BVExDTE1TZWJaTWt1MmpNVTlKZ3M4cWkwZXRkbm8zNHlLa3l0ZFNkMU12Q1RITXVEZjR3N2tkdXpuM1pRM1dUOExLREd1NTZEc2lwbVk2Z2hKRlNKemlqb3AyYXk0SXZqZmhabEpEMHBuYnc?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-09/heart-researchers-unpack-neutral-findings-from-zeus-an-anti-inflammatory*
